ACC 2021: The VOYAGER PAD Trial

Published: 27 May 2021

  • Views:

    Views Icon 85
  • Likes:

    Heart Icon 0

Prof Rupert Bauersachs (Clinic Darmstadt, Darmstadt, DE) discusses the results from the VOYAGER PAD trial. The aim of the trial was to evaluate rivaroxaban/aspirin compared with placebo/aspirin among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization.


  1. What is the VOYAGER PAD Trial and what does it aim to address?
  2. What was the study design, patient population and endpoints?
  3. What are the main findings to date?
  4. What conclusions can be made and what are the implications on practice?
  5. What are the next steps?

Recorded remotely from Darmstadt, 2021. 

Editor: Mirjam Boros


Videography: Oliver Miles, Dan Brent